natgillin/translations-raw huggingface dataset:
The residual medicinal product must not be flushed in the administration tubing as rapid infusion of busulfan has not been tested and is not recommended.
Preostali lijek ne smije se ispirati u cijevima za primjenu jer brza infuzija busulfana nije testirana i ne preporučuje se.
the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent.
sadržaj štrcaljke mora se ubrizgati u intravensku vrećicu (ili štrcaljku) koja već sadrži izračunatu količinu odabranog otapala.
The dose proportional increase of busulfan exposure was demonstrated following intravenous busulfan up to 1 mg/kg.
Dokazano je povećanje izloženosti busulfanu proporcionalno dozi nakon intravenoznog busulfana do 1 mg/kg.
D: dose of busulfan (see SPC section 4.2)
D: doza busulfana (vidjeti dio 4.2)
The most serious side effects of busulfan therapy or the transplant procedure may include decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion), infection, liver disorders including blocking of a liver vein, graft versus host disease (the graft attacks your body) and pulmonary complications.
Najozbiljnije nuspojave terapije lijekom Busulfan Fresenius Kabi ili postupka presađivanja mogu uključivati smanjenje cirkulirajućeg broja krvnih stanica (namjerni učinak lijeka radi pripreme za transplantacijsku infuziju), infekciju, poremećaje jetre uključujući začepljenje jetrene vene, reakciju presatka na domaćina (presadak napada Vaše tijelo) i plućne komplikacije.
* reported in post-marketing experience ** include haemorrhagic cystitis induced by viral infection
* prijavljeno nakon stavljanja lijeka u promet ** uključuje hemoragični cistitis induciran virusnom infekcijom
Nervous system: confusion, nervous system disorders.
Živčani sustav: smetenost, poremećaji živčang sustava.
These include infection and Graft-versus host disease (GVHD) which although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT.
Graft-Versus Host Desease), koji su, iako nisu bili izravno povezani, bili glavni uzroci pobolijevanja i smrtnosti, naročito kod alogeničnog HPCT.
The pharmacokinetics of busulfan has been investigated.
Ispitivana je farmakokinetika busulfana.
Documentation on the safety and efficacy of busulfan in combination with fludarabine (FB) prior to allogeneic HPCT derives from the literature review of 7 published studies involving 731 patients with myeloid and lymphoid malignancies reporting the use of intravenous busulfan infused once daily instead of four doses per day.
Dokumentacija o sigurnosti i djelotvornosti Busilvexa u kombinaciji s fludarabinom (FB) prije alogenog HPCT-a potječe iz pregleda literature 7 objavljenih ispitivanja koja uključuju 731 bolesnika s mijeloidnim ili limfoidnim malignim bolestima koja bilježe primjenu intravenskog busulfana infundiranog jednom dnevno umjesto četiri doza dnevno.
Hyperglycaemia Hypocalcaemia Hypokalaemia Hypomagnesaemia Hypophosphatemia
Anoreksija Hiperglikemija Hipokalcijemija Hipokalijemija Hipomagnezijemija Hipofosfatemija
During clinical trials with intravenous busulfan administered as 0.80 mg/kg four-times daily, 90% of patients AUCs were below the upper AUC limit (1500 µmol/L.minute) and at least 80% were within the targeted therapeutic window (900 - 1500 µmol/L.minute).
Tijekom kliničkih ispitivanja s intravenskim busulfanom primijenjenim u dozi od 0,80 mg/kg četiri puta dnevno, 90% vrijednosti AUC svih bolesnika bilo je ispod gornje granice AUC (1500 μmol/l.minuta) i najmanje 80% bilo je unutar ciljanog terapijskog okvira (900-1500 μmol/l.minuta).
In adults Busulfan Fresenius Kabi is used in combination with cyclophosphamide or fludarabine.
U odraslih se Busulfan Fresenius Kabi primjenjuje u kombinaciji s ciklofosfamidom ili fludarabinom.
The recommended dose of Busulfan Fresenius Kabi in combination with cyclophosphamide or melphalan is based on your body weight varying between 0.8 and 1.2 mg/kg.
Preporučena doza lijeka Busulfan Fresenius Kabi u kombinaciji s ciklofosfamidom ili melfalanom temelji se na Vašoj tjelesnoj težini i varira između 0,8 i 1,2 mg/kg.
Busulfan must not be infused concomitantly with another intravenous solution.
Busulfan se ne smije infundirati istodobno s drugom intravenskom otopinom.
At 2 years, the cumulative incidence of NRM was 11.3% (95%CI, 5.5-19.3%), and that of relapse or progression from allo-HCT was 43.8% (95CI, 31.1-55.7%).
Nakon 2 godine, ukupna incidencija smrtnosti koja nije povezana s relapsom iznosila je 11,3% (95%tni CI, 5,5 - 19,3%), a ona od relapsa ili progresije od alogenog HCT-a iznosila 43,8% (95%-tni CI, 31,1 - 55,7%).
Data from a recently completed prospective multicentre phase 2 study including 80 patients, aged 18 to 65 years old, diagnosed with different hematologic malignancies who underwent allo-HCT with an FB (3 days of busulfan) reduced intensity conditioning regimen became available.
Postali su dostupni podaci iz nedavno završenog, prospektivnog, multicentričnog ispitivanja faze 2 koje je uključivalo 80 bolesnika, u dobi od 18 do 65 godina, s dijagnozom različitih hematoloških malignih bolesti, koji su se podvrgnuli alogenom HCT-u s protokolom kondicioniranja smanjenog intenziteta s FB-om (3 dana busulfana).
No evidence of an induction effect of phenytoin has been seen on busulfan data.
Nisu zabilježeni dokazi indukcijskog učinka fenitoina iz podataka o busulfanu.
Busulfan in combination with fludarabine (FB)
Busulfan u kombinaciji s fludarabinom (FB)
8 MARKETING AUTHORISATION NUMBER(S) EU/1/14/951/001
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/14/951/001
No patients were discontinued from treatment due to adverse reactions related to busulfan.
Niti jedan bolesnik nije prekinuo liječenje zbog nuspojava povezanih s busulfanom.
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2-hour intravenous infusion for a total of 16 doses over four days.
Farmakokinetika intravenskog busulfana ispitivana je na 124 bolesnika koje je bilo moguće ocijeniti nakon dvosatne intravenske infuzije ukupno 16 doza tijekom četiri dana.
The median duration of neutropenia was 6 days and 9 days for autologous and allogeneic patients.
Medijan trajanja neutropenije bio je 6 dana i 9 dana za autologne i alogene bolesnike.
In the absence of haematopoietic progenitor cell transplantation, the recommended dose of busulfan would constitute an overdose of busulfan.
U odsutnosti presađivanja hematopoetskih progenitorskih stanica preporučena doza busulfana uzrokovala bi predoziranje busulfanom.
Using a non polycarbonate syringe fitted with a needle:
Upotrebom nepolikarbonatnih štrcaljki opremljenih iglom:
No interaction was observed when busulfan was combined with fluconazole (antifungal agent).
Nisu zabilježene interakcije kada je busulfan kombiniran s flukonazolom (sredstvom protiv gljivica).
The literature on busulfan suggests a therapeutic AUC window between 900 and 1500 µmol/L.minute per administration (equivalent to a daily exposure between 3600 and 6000 µmol/L.minute).
U literaturi o busulfanu preporučen je terapijski AUC okvir između 900 i 1500 μmol/l.minutu po primjeni (ekvivalentno dnevnoj izloženosti između 3600 i 6000 µmol/l.minutu.
Special caution should be exercised when administering the recommended dose of busulfan to patients with a history of seizures.
Posebna pozornost potrebna je kada se preporučena doza busulfana daje bolesnicima s anamnezom napadaja.
For storage conditions after dilution of the medicinal product see section 6.3.
Uvjete čuvanja nakon razrjeđivanja lijeka, vidjeti u dijelu 6.3.
Therefore, men treated with busulfan are advised not to father a child during and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with busulfan.
Stoga se muškarcima liječenim busulfanom preporuča da tijekom liječenja i do 6 mjeseci nakon liječenja ne začinju dijete i da zatraže savjet o kriokonzervaciji sperme prije liječenja zbog mogućnosti ireverzibilne neplodnosti uslijed liječenja busulfanom.
Busulfan is for intravenous use.
Busulfan je za intravensku primjenu.
10 ml of concentrate for solution for infusion in clear colourless glass vials (type I) with teflon faced rubber stopper and sealed with aluminium flip-off seal.
10 ml koncentrata za otopinu za infuziju u prozirnim staklenim bočicama (tip I) s gumenim zatvaračem presvučenim teflonom i aluminijskim "flip-off" zaštitnim zatvaračem.
Busulfan Fresenius Kabi is supplied in colourless glass vials, each vial containing 60 mg of busulfan.
Busulfan Fresenius Kabi se isporučuje u bezbojnim staklenim bočicama, svaka bočica sadrži 60 mg busulfana.
Busulfan Fresenius Kabi may interact with other medicines.
Busulfan Fresenius Kabi može međusobno djelovati s drugim lijekovima.
Ventricular Extrasystoles Bradycardia
Ventrikularne ekstrasistole Bradikardija
The incidence of acute graft versus host disease (a-GVHD) data was collected in allogeneic patients (n=28).
Podaci o pojavnosti akutne reakcije presatka na domaćina (a-GVHD) prikupljeni su od alogenih bolesnika (n=28).
The amount of Busulfan Fresenius Kabi and diluent to be administered would be calculated as follows: for a patient with a Y kg body weight:
Količina lijeka Busulfan Fresenius Kabi i otapala koji se moraju primijeniti izračunavaju se na sljedeći način: za bolesnika s tjelesnom težinom Y kg:
Busulfan Fresenius Kabi is a potent cytotoxic medicine that results in profound decrease of blood cells.
Busulfan Fresenius Kabi je snažan, citotoksičan lijek koji dovodi do izrazitog smanjenja broja krvnih stanica.
Busulfan Fresenius Kabi is used in adults, new-born infants, children and adolescents as a treatment prior to transplantation.
Busulfan se primjenjuje u odraslih, novorođenčadi, djece i adolescenata kao liječenje prije presađivanja.
What Busulfan Fresenius Kabi contains - The active substance is busulfan.
Što Busulfan Fresenius Kabi sadrži - Djelatna tvar je busulfan.
The entire prescribed busulfan dose should be delivered over two or three hours depending on the conditioning regimen.
Ukupna propisana doza busulfana mora se primijeniti tijekom dva ili tri sata, ovisno o protokolu kondicioniranja.
What Busulfan Fresenius Kabi is and what it is used for
Što je Busulfan Fresenius Kabi i za što se koristi
In adult and paediatric studies, patients received either phenytoin or benzodiazepines as seizure prophylaxis treatment (see sections 4.4 and 4.5).
U ispitivanjima na odraslima i djeci bolesnici su primali fenitoin ili benzodiazepine kao profilaktičnu terapiju napadaja (vidjeti dijelove 4.4 i 4.5).
A reduced incidence of Hepatic Veno Occlusive Disease (HVOD) and other regimen-related toxicity have been observed in patients when the lag time between the last dose of oral busulfan and the first dose of cyclophosphamide is > 24hours.
Hepatic Veno Occlusive Disease, HVOD) i toksičnosti povezane s ostalim protokolima zabilježena je u bolesnika kada je vrijeme latencije između posljednje peroralne doze busulfana i prve doze ciklofosfamida > 24 sata.
The recommended posology for children as detailed in section 4.2 enabled over 70% up to 90% of children ≥ 9kg in achieving the therapeutic window (900 - 1500 µmol/L.minute).
Preporučeno doziranje za djecu navedeno u dijelu 4.2 omogućilo je da više od 70% pa sve do 90% djece ≥ 9 kg postigne terapijski okvir (900-1500 μmol/l.minuta).
What Busulfan Fresenius Kabi looks like and contents of the pack Busulfan Fresenius Kabi consists of a concentrate for solution for infusion.
Kako Busulfan Fresenius Kabi izgleda i sadržaj pakiranja Busulfan Fresenius Kabi se sastoji od koncentrata za otopinu za infuziju.
Documentation on the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/or autologous HPCT derives from two clinical trials (OMC-BUS-4 and OMC-BUS-3).
Dokumentacija o sigurnosti primjene i djelotvornosti busulfana u kombinaciji s ciklofosfamidom u protokolu BuCy2 prije konvencionalnog alogenog i/ili autolognog HPCT-a potječe iz dva klinička ispitivanja (OMC-BUS-4 i OMC-BUS-3).
Therefore it is advised not to father child during the treatment and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility (see section 4.4).
Stoga se bolesnicima preporučuje da tijekom liječenja i do 6 mjeseci nakon liječenja ne začinju dijete te da, zbog mogućnosti ireverzibilne neplodnosti, prije liječenja zatraže savjet o kriokonzervaciji sperme (vidjeti dio 4.4).
Pack size 1 pack containing 8 vials (8 cartons of 1 vial).
Veličina pakiranja Jedno pakiranje koje se sastoji od 8 bočica (8 pojedinačnih kutija sa po 1 bočicom).
The effect of those anticonvulsant agents on busulfan pharmacokinetics was investigated in a phase II study (see section 4.5).
Učinak tih antikonvulzivnih sredstava na farmakokinetiku busulfana ispitivan je u fazi II ispitivanja (vidjeti dio
The incidence of acute graft versus host disease (a-GVHD) data was collected in OMC-BUS-4 study (allogeneic)(n=61) .
Podaci o incidenciji akutne reakcije presatka na domaćina (a-GVHD) prikupljeni su u ispitivanju OMC-BUS-4 (alogeno) (n=61).
The concomitant systemic administration of phenytoin to patients receiving high-dose of oral busulfan has been reported to increase busulfan clearance, due to induction of glutathion-S-transferase whereas no interaction has been reported when benzodiazepines such as diazepam, clonazepam or lorazepam have been used to prevent seizures with high-dose busulfan.
Prijavljeno je da istodobna sistemska primjena fenitoina u bolesnika koji primaju visoke peroralne doze busulfana povećava klirens busulfana zbog indukcije glutation-S-transferaze, dok za primjenu benzodiazepina kao što su diazepam, klonazepam ili lorazepam koji se primjenjuju za sprječavanje napadaja uz visoke doze busulfana nije prijavljena interakcija.
Busulfan is administered as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses prior to cyclophosphamide or melphalan and haematopoietic progenitor cell transplantation (HPCT).
Busulfan se primjenjuje kao dvosatna infuzija svakih 6 sati tijekom 4 uzastopna dana odnosno ukupno 16 doza prije ciklofosfamida ili melfalana i presađivanja hematopoetskih progenitorskih stanica (HPCT).
However a higher variability was observed in children < 9 kg leading to 60% of children achieving the therapeutic window (900 - 1500 µmol/L.minute).
No u djece < 9 kg postignuta je veća varijabilnost koja je dovela do toga da 60% djece postigne terapijski okvir (900-1500 μmol/l.minuta).
In adults and children studies, data with busulfan were obtained when using concomitant administration of either phenytoin or benzodiazepines for seizure prophylaxis.
U ispitivanjima na odraslima i djeci podaci za busulfan dobiveni su kada se za profilaksu napadaja istodobno primjenjivao ili fenitoin ili benzodiazepini.
Adjusted ideal body weight (AIBW) is calculated as follows: AIBW= IBW + 0.25x (actual body weight-IBW).
Prilagođena idealna tjelesna težina (PITT) izračunava se na sljedeći način: PITT = ITT + 0,25x (stvarna tjelesna težina - ITT).
Busulfan will be administered once daily during 2 or 3 consecutive days prior to transplant.
- Busulfan Fresenius Kabi će se primjenjivati jednom dnevno tijekom 2 ili 3 uzastopna dana prije presađivanja.
Documentation of the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy4 or with melphalan in the BuMel regimen prior to conventional allogeneic and/or autologous HPCT derives from clinical trial F60002 IN 101 G0.
Dokumentacija o sigurnosti i djelotvornosti Busilvexa u kombinaciji s ciklofosfamidom u protokolu BuCy4 ili s melfalanom u protokolu BuMel prije konvencionalnog alogenog i/ili autolognog HPCT-a potječe iz kliničkog ispitivanja F60002 IN 101 G0.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 60 mg/10 ml OTHER Cytotoxic
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 60 mg/10 ml
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109/l was 21 days (range 12-47 days) in allogenic patients, and 11 days (range 10-15 days) in autologous patients.
Vrijeme do apsolutnog broja neutrofila (ABN) većeg od 0,5x109 /l bilo je 21 dan (raspon od 12-47 dana) u alogenih bolesnika i 11 dana (raspon od 10-15 dana) u autolognih bolesnika.
The safety profile of busulfan combined with fludarabine (FB) has been examined through a review of adverse reactions reported in published data from clinical trials in RIC regimen.
Sigurnosni profil lijeka busulfan u kombinaciji s fludarabinom (FB) ispitan je putem pregleda nuspojava zabilježenih u objavljenim podacima iz kliničkih ispitivanja protokola kondicioniranja smanjenog intenziteta.
OTHER SPECIAL WARNING IF NECESSARY Cytotoxic
DRUGO(A) POSEBNO(A) UPOZORENJE, AKO JE POTREBNO Citotoksično
From published studies in adults, administration of itraconazole to patients receiving high-dose busulfan may result in reduced busulfan clearance.
U objavljenim ispitivanjima na odraslima pokazalo se da primjena itrakonazola na bolesnicima koji primaju visoke doze busulfana može rezultirati smanjenim klirensom busulfana.
Busulfan administration should be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.
Primjenu busulfana mora nadzirati liječnik iskusan u terapiji kondicioniranja koje prethodi presađivanju hematopoetskih progenitorskih stanica.
- Busulfan will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
- Busulfan se primjenjuje u dozi od 3,2 mg/kg kao trosatna infuzija jednom dnevno odmah nakon fludarabina u 2 ili 3 uzastopna dana.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial of 10 ml.
OBLIK I SADRŽAJ Koncentrat za otopinu za infuziju 1 bočica od 10 ml.
Renal and urinary disorders It has been suggested that conditioning regimens containing fludarabine were associated with higher incidence of opportunistic infections after transplantation because of the immunosuppressive effect of fludarabine.
Pretpostavlja se da su protokoli kondicioniranja koji sadrže fludarabin povezani s većim incidencijama oportunističkih infekcija nakon presađivanja zbog imunosupresivnog učinka fludarabina.
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109 /l was 13 days (range 9-29 days) in allogenic patients (OMC-BUS 4), and 10 days (range 8-19 days) in autologous patients (OMC-BUS 3).
Vrijeme do apsolutnog broja neutrofila (ABN) većeg od 0,5x109 /l bilo je 13 dana (raspon od 9-29 dana) u alogenih bolesnika (OMC-BUS 4) i 10 dana (raspon od 8-19 dana) u autolognih bolesnika (OMC-BUS 3).
Read this guide prior to the preparation and administration of Busulfan Fresenius Kabi.
Pročitajte ove upute prije pripreme i primjene Busulfan Fresenius Kabia.
• Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques.
• Busulfan Fresenius Kabi mora pripremiti zdravstveni djelatnik koristeći se sterilnim tehnikama prijenosa.
As with other cytotoxic compounds, caution should be exercised in handling and preparing the busulfan solution: - The use of gloves and protective clothing is recommended.
U rukovanju otopinom lijeka Busulfan Fresenius Kabi i njenoj pripremi je potreban oprez, kao i s drugim citotoksičnim spojevima: - Preporučuje se uporaba rukavica i zaštitne odjeće.
Busulfan followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.
Busulfan nakon kojeg slijedi ciklofosfamid (BuCy4) ili melfalan (BuMel) indiciran je kao terapija kondicioniranja prije konvencionalnog presađivanja hematopoetskih progenitorskih stanica u pedijatrijskih bolesnika.
There is no known antidote to busulfan other than haematopoietic progenitor cell transplantation.
Ne postoji poznati protulijek za busulfan osim presađivanja hematopoetskih progenitorskih stanica.
Do not use this medicine after the expiry date which is stated on the vial label and the carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici bočice i kartonskoj kutiji iza oznake „Rok valjanosti“.
Renal: increase in creatinine elimination, discomfort in urination, and decrease in urine output and bloody urine.
Bubrezi: povećanje uklanjanja kreatinina, nelagoda pri mokrenju, smanjeno izlučivanje urina i krvavi urin.
Busulfan followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.
Busulfan nakon kojeg slijedi ciklofosfamid (BuCy2) indiciran je kao terapija kondicioniranja prije konvencionalnog presađivanja hematopoetskih progenitorskih stanica (HPCT, engl. haematopoietic progenitor cell transplantation) u odraslih bolesnika kada se ta kombinacija smatra najboljom raspoloživom mogućnošću.
Busulfan Fresenius Kabi is supplied as a clear colourless viscous solution in 10 ml clear, colourless glass vials (type I).
Busulfan Fresenius Kabi se na tržištu nalazi kao bistra, bezbojna, viskozna otopina u prozirnim, bezbojnim, staklenim bočicama od 10 ml (staklo tip I).
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 8 vials of 10 ml 60 mg per vial
OBLIK I SADRŽAJ Koncentrat za otopinu za infuziju 8 bočica od 10 ml
Clear, colourless viscous solution.
Bistra, bezbojna viskozna otopina.
• Quantity of Busulfan Fresenius Kabi:
• Količina Busulfan Fresenius Kabi:
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when stored at 25°C ± 2°C or 12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time).
Kemijska i fizička stabilnost u primjeni nakon razrjeđivanja u 5%-tnoj otopini glukoze ili otopini natrijeva klorida 9 mg/ml (0,9%) za injekciju dokazana je za 8 sati (uključujući vrijeme infuzije) nakon razrjeđivanja ako se čuva na temperaturi od 25°C ± 2°C ili 12 sati nakon razrjeđivanja ako se čuva na temperaturi od 2°C - 8°C nakon čega je uslijedilo 3 sata čuvanja na temperaturi od 25°C ± 2°C (uključujući vrijeme infuzije).
Do not use Busulfan Fresenius Kabi: - if you are allergic to busulfan or any of the other ingredients of this medicine listed in section 6.
Nemojte primjenjivati Busulfan Fresenius Kabi: - ako ste alergični na busulfan ili neki drugi sastojak lijeka Busulfan Fresenius Kabi naveden u dijelu 6, - ako ste trudni ili mislite da ste možda trudni.
Busulfan in combination with cyclophosphamide
Busulfan u kombinaciji s ciklofosfamidom
Blood: decrease of blood circulating cells (red and white) and platelets.
Krv: smanjenje krvnih stanica (crvenih i bijelih) i trombocita u krvotoku.Invekcije.
Busulfan following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.
Busulfan koji slijedi nakon fludarabina (FB) indiciran je kao terapija kondicioniranja prije presađivanja hematopoetskih progenitorskih stanica (HPCT) u odraslih bolesnika koji su kandidati za protokol kondicioniranja smanjenog intenziteta (RIC).
Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques.
Busulfan Fresenius Kabi mora pripremiti zdravstveni djelatnik koristeći se sterilnim tehnikama prijenosa.
Other medicines and Busulfan Fresenius Kabi Tell your doctor if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obavijestite svog liječnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući lijekove dobivene bez recepta.